OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Ovid Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$2.17+0.02 (+0.93%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Ovid Therapeutics Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Cash & Equivalents	13	28	29	47	190	72	42	36	87	52	70	4.85
Short-Term Investments	56	27	79	84	0	–	35	5.01	–	–	–	–
Cash & Short-Term Investments	90	53	106	129	188	72	77	42	87	52	70	4.85
Prepaid Expenses & Other	4.73	2.87	3.76	2.38	2.68	2.67	1.94	2.17	1.46	0.22	–	–
Total Current Assets	74	56	110	131	190	75	80	44	89	52	–	–
Property, Plant & Equipment	0.25	0.43	0.77	1.15	0.24	0.14	0.07	0.07	0.05	0.04	–	–
Accumulated Depreciation	-1.59	-1.41	-1.00	-0.58	-0.26	-0.19	-0.13	-0.09	-0.05	-0.02	–	–
Long-Term Investments	21	0	18	5.62	1.63	0	–	–	–	–	–	–
Equity Method Investments	–	–	–	5.10	1.60	0	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	12	13	14	15	0	–	–	–	–	–	–	–
Intangible Assets	0	0.10	0.20	0.22	0.16	0.32	0.47	0.39	0.12	0.11	–	–
Other Long-Term Assets	0	0.09	0.21	0.26	0.26	0.32	0.47	0.39	0.12	0.17	–	–
Total Assets	151	92	144	155	195	76	81	48	89	53	–	–
Accounts Payable	1.96	3.19	3.70	1.95	7.13	5.45	3.26	3.76	2.03	0.86	–	–
Accrued Expenses	4.90	5.99	6.52	4.50	7.67	12	7.27	5.09	4.00	2.88	–	–
Current Portion of Leases	1.43	1.34	1.25	0.53	0	–	–	–	–	–	–	–
Deferred Revenue (Current)	–	–	–	–	0	2.21	–	–	–	–	–	–
Total Current Liabilities	8.29	11	11	6.99	15	22	11	8.84	6.02	3.73	–	–
Long-Term Leases	12	13	15	16	0	–	–	–	–	–	–	–
Operating Lease Liabilities	13	15	16	17	0	–	–	–	–	–	–	–
Total Liabilities	20	24	56	23	15	32	11	8.84	6.02	3.73	–	–
Preferred Stock	0	0	0	0.00	0.00	0.00	0.00	–	–	–	–	–
Common Stock	0.13	0.07	0.07	0.07	0.07	0.07	0.05	0.02	0.02	0.01	–	–
Additional Paid-In Capital	452	372	366	358	351	338	283	191	184	85	–	–
Retained Earnings	-322	-304	-278	-226	-171	-294	-213	-153	-101	-36	–	–
Comprehensive Income & Other	-0.20	-0.04	0.00	-0.04	0	–	0.00	0.00	–	–	–	–
Shareholders' Equity	131	68	88	132	180	44	70	39	83	49	68	4.74
Total Equity	131	68	88	132	180	44	70	39	83	49	68	4.74
Total Liabilities & Equity	151	92	144	155	195	76	81	48	89	53	–	–
Shares Outstanding(shares)	130	71	71	70	70	66	55	25	25	9.84	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -3686.7%
Net margin: -2178.9%
Return on equity, FY2025: -17.5%

Financial strength

Current ratio: 12.39
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 113.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –